Medicine and Dentistry
Multiple Myeloma
100%
Frailty
65%
Overall Survival
64%
Quality of Life
57%
Metastatic Breast Cancer
57%
Bortezomib
32%
Survival Rate
32%
Prognostic Factor
30%
B-Cell Chronic Lymphocytic Leukemia
28%
Disseminated Intravascular Coagulation
28%
D-Dimer
28%
Rituximab
28%
Sarcopenia
28%
Venetoclax
28%
Cyclophosphamide
28%
Fludarabine
28%
Geriatrics
28%
Obinutuzumab
28%
Clinical Trial
28%
Trastuzumab
28%
Daratumumab
28%
Thalidomide
28%
Dexamethasone
28%
Receptor
28%
Targeted Therapy
28%
Survival Prediction
28%
Acute Myeloid Leukemia
28%
Chronic Myelogenous Leukemia
28%
Treatment Duration
28%
Myeloma
22%
Hazard Ratio
21%
Induction Chemotherapy
20%
Sarcopenic Obesity
19%
Health Status
17%
Diseases
16%
Body Mass Index
14%
Frailty Index
14%
Recurrent Disease
14%
Patient-Reported Outcome
11%
Progression Free Survival
10%
Skeletal Muscle
9%
Minimal Residual Disease
7%
Fibrinolysis
7%
False Negative Result
7%
Malignant Neoplasm
7%
Prevalence
7%
Proportional Hazards Model
6%
Physical Performance
5%
Nutrition
5%
Cancer Treatment
5%
Pharmacology, Toxicology and Pharmaceutical Science
Frailty
76%
Multiple Myeloma
68%
Chronic Lymphatic Leukemia
57%
Metastatic Breast Cancer
57%
Chemotherapy
42%
Overall Survival
36%
Health Status
34%
Paclitaxel
28%
Esophagus Cancer
28%
Cyclophosphamide
28%
Trastuzumab
28%
Obinutuzumab
28%
Rituximab
28%
Venetoclax
28%
Survival Rate
28%
Clinical Trial
28%
Sarcopenia
28%
Fludarabine
28%
Receptor
28%
Survival Prediction
28%
Myeloma
20%
Pharmacokinetics
20%
Sarcopenic Obesity
19%
Malignant Neoplasm
15%
Melphalan
9%
Bortezomib
9%
Prednisone
9%
Deterioration
9%
Polyneuropathy
9%
Phase II Trials
9%
Diseases
8%
Prevalence
7%
Hematologic Malignancy
6%
Minimal Residual Disease
5%
Dyspnea
5%
Comorbidity
5%
Nursing and Health Professions
Overall Survival
57%
Remission
32%
Metastatic Breast Cancer
28%
Muscle Mass
28%
Survival Prediction
28%
Hospital Volume
28%
Multiple Myeloma
28%
Frailty
28%
Acute Myeloid Leukemia
28%
Induction Chemotherapy
20%
Sarcopenic Obesity
19%
Hazard Ratio
16%
Confidence Interval
16%
Clinical Practice
8%
Treatment Duration
8%
Myeloma
5%